IP Library Granted Patent US 9,499,585
Granted Patent B2
US 9,499,585 · App. 14/401,353 · Granted Nov 22, 2016

Bioactive peptide complexes

Inventors: Oleg Ivanovich Kiselev (St. Petersburg, RU); Feliks Ivanovich Ershov (Moscow, RU)
Assignee: Alloferon Inc.
C07K7/08C07K7/06A61K38/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,499,585
App. No.
14/401,353
Granted
Nov 22, 2016
Kind
B2
Abstract

Herein disclosed are bioactive peptides and proteins having immunomodulating and antiviral activity, more particularly histidine-rich bioactive peptide complexes having the following structural formula (SEQ ID NO: 23): wherein: X 1 is absent or contains not less than 1 amino acid and R1 and R2 are peptide chains containing the amino acid residues His or Cys, that interact with transition metal ions. Whereas R1 may contain up to 5 amino acid residues or alternatively be absent, R2 contains up to 3 amino acid residues or is alternatively absent. Such peptide complexes, primarily alloferon family peptides with Zn ions, enable the design of drugs based on an understanding of drug target structure and thus enable the creation of drugs with targeted mechanism of action.

Claims (6)

1. A peptide complex organized in three-dimensional structure and characterized by general structural formula (SEQ ID NO: 29):

wherein:

X 1 is selected from the group consisting of Gln, Ser, Asn, Val, Ala, Phe, and Asp or alternatively is absent; and

R1 and R2 comprise peptide chains that contain His amino acid residues and interact with transition metal ions, further wherein R1 is selected from the group consisting of: His-Gly-Val-Ser-Gly- (SEQ ID NO: 30), His-Gly-Ser-Asp-Gly- (SEQ ID NO: 32), and Gly-His-Gly-Asp-Ser-Gly- (SEQ ID NO: 33); and R2 is selected from the group consisting of: -Val-His-Gly, -Val-Phe-Val, -Val-His, -Val-Asp or alternatively is absent.

2. The peptide complex according to claim 1 , wherein said peptide complex induces interferon synthesis.

3. The peptide complex according to claim 1 , wherein said peptide complex has antiviral activity.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE COUNTRY NAME FOR THE ASSIGNEE PREVIOUSLY RECORDED ON REEL 040361 FRAME 0660. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Dec 5, 2016
From: AT-PHARMA CO., LTD.
To: ALLOFERON INC.
Reel/Frame 040854/0341 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 17, 2016
From: AT-PHARMA CO., LTD.
To: ALLOFERON INC.
Reel/Frame 040361/0660 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 19, 2016
From: AT-PHARMA CO., LTD.
To: AT PHARMA CO., LTD.
Reel/Frame 038649/0437 →
CHANGE OF NAME Recorded Sep 8, 2015
From: ALLOTECH CO., LTD.
To: AT-PHARMA CO., LTD.
Reel/Frame 036563/0795 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2014
From: KISELEV, OLEG IVANOVICH; ERSHOV, FELIKS IVANOVICH
To: ALLOTECH CO., LTD.
Reel/Frame 034175/0570 →
Continuity (1)
Related Publication 20150299257A1 · Oct 22, 2015